Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M C Cox

Showing results (31-40 of 46) with videos related to

Pageof 5
Sort By:
Blood|January 1, 1997
Biological pattern of AML-M0 versus AML-M1: responseA Venditti, G Del Poeta, F Buccisano, et al.
Blood|July 10, 1998
Biological features of acute myeloid leukemia in the elderlyA Venditti, G Del Poeta, F Buccisano, et al.
Annals of Hematology|April 1, 1996
Minimally differentiated acute myeloid leukemia (AML-M0): a distinct clinico-biologic entity with poor prognosisS Amadori, A Venditti, G Del Poeta, et al.
Leukemia & Lymphoma|December 24, 1997
P-glycoprotein expression in de novo acute myeloid leukemiaG Del Poeta, A Venditti, G Aronica, et al.
Leukemia|July 17, 1998
Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemiaA Venditti, G Del Poeta, F Buccisano, et al.
Leukemia Research|June 22, 1999
P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemiaG Del Poeta, A Venditti, R Stasi, et al.
Leukemia|July 14, 2006
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemiaF Buccisano, L Maurillo, V Gattei, et al.
Frontiers in Oncology|March 27, 2026
Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional networkS Pelliccia, A Di Rocco, G Palumbo, et al.
Blood|January 15, 1997
Minimally differentiated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypesA Venditti, G Del Poeta, F Buccisano, et al.
Frontiers in Oncology|March 4, 2026
Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional networkS Pelliccia, A Di Rocco, G Palumbo, et al.
Pageof 5

Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
Blood|January 1, 1997
Biological pattern of AML-M0 versus AML-M1: responseA Venditti, G Del Poeta, F Buccisano, et al.
Blood|July 10, 1998
Biological features of acute myeloid leukemia in the elderlyA Venditti, G Del Poeta, F Buccisano, et al.
Annals of Hematology|April 1, 1996
Minimally differentiated acute myeloid leukemia (AML-M0): a distinct clinico-biologic entity with poor prognosisS Amadori, A Venditti, G Del Poeta, et al.
Leukemia & Lymphoma|December 24, 1997
P-glycoprotein expression in de novo acute myeloid leukemiaG Del Poeta, A Venditti, G Aronica, et al.
Leukemia|July 17, 1998
Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemiaA Venditti, G Del Poeta, F Buccisano, et al.
Leukemia Research|June 22, 1999
P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemiaG Del Poeta, A Venditti, R Stasi, et al.
Leukemia|July 14, 2006
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemiaF Buccisano, L Maurillo, V Gattei, et al.
Frontiers in Oncology|March 27, 2026
Correction: Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional networkS Pelliccia, A Di Rocco, G Palumbo, et al.
Blood|January 15, 1997
Minimally differentiated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypesA Venditti, G Del Poeta, F Buccisano, et al.
Frontiers in Oncology|March 4, 2026
Siltuximab as a first-line therapy for idiopathic multicentric Castleman disease: a retrospective analysis based on the SiMuLa study of the Italian regional networkS Pelliccia, A Di Rocco, G Palumbo, et al.
Pageof 5